抗血小板治疗：强化抑或适度？
西红柿汁具有潜在的抗血小板治疗前景。
抗血小板治疗有助于减少心、脑血管不良事件的发生。
So antiplatelet cure conduce to reduce the harmful events of cardia and cerebrovascular disorder.
抗血小板治疗是缺血性卒中二级预防的重要措施之一。
Antiplatelet therapy is one of the important measures in the secondary prevention of ischemic stroke.
如果是金属裸支架，我们维持双重抗血小板治疗几个月。
If it is a bare metal stent, we keep up the dual anti-platelet therapy for just a few months.
这些结果都强调了对于糖尿病患者抗血小板治疗方案的个体化需要。
These findings underscore the need of individualized antiplatelet treatment regimens in diabetic patients.
心血管事件的二级预防：抗血小板治疗药物越“先进”越完美吗？
Antiplatelet Therapy for Secondary Prevention of Cardiovascular Events: More "Advanced" Drug, More Perfect?
目的：观察强化抗血小板治疗急性缺血性脑卒中的疗效及安全性。
Objective: To observe the therapeutic effect and safety of Strengthening anti-platelet in Acute ischemic stroke.
FDA也推荐介入治疗后至少延长一年对病人进行双重抗血小板治疗。
The FDA also recommends prolonged dual antiplatelet therapy for at least a year following the intervention.
《国际循环》：您能谈谈acs患者早期抗血小板治疗的最佳策略选择吗？
International Circulation: Could you please talk about the choice of optimal strategy of early antiplatelet therapy in patients with ACS?
当然，在抗血小板治疗时，可能出现各种原因导致病人无法接受抗血小板治疗。
Of course all those patients to have problems with antiplatelet therapy for whatever reason had to refuse antiplatelet.
双重抗血小板治疗的最佳持续时间取决于特定心脏指征(见本增刊中其他篇目)。
The optimal duration of dual antiplatelet therapy depends on the specific cardiac indication (see other articles in this supplement) for recommended for specific indications.
最大的变化是抗血小板药物的使用率增加，比如双重抗血小板治疗以及抗凝治疗。
The biggest change has been in the increased use of international therapy and anti-platelet agents as dual anti-platelet therapy, and antithrombotics.
目的：观察分析单独抗血小板治疗与联合抗凝治疗在心源性脑梗塞中的临床意义。
Objective Observation and analysis of separate United anticoagulation and antiplatelet therapy in the treatment of cardiac cerebral infarction clinical significance.
第一年结束的时候，患者被随机分为继续双重抗血小板治疗组和停止抗凝治疗组。
At the end of one year, they are randomized to continue their dual anti-platelet therapy or having it stopped.
《国际循环》：慢性肾功能不全的患者抗血小板治疗的实施方法与ACS患者有何差别？
International Circulation: For the patients with chronic renal function failure, is there any difference from other patients with ACS in the management of antiplatelet therapy?
这就是我们需要的这种研究，目的是最终决定我们真正需要持续双重抗血小板治疗多长时间。
That is the kind of study that we need to have in order to make a final decision about how long we really need to continue dual anti-platelet therapy.
我们推测，在后来的队列研究中，临床医师更加重视DES的风险，并延长了抗血小板治疗时间。
We speculate that in the later cohort clinicians were more aware of the risk of DES and prolonged antiplatelet therapy.
抗血小板治疗而带来的好处，如阿斯匹林是建立在预防心血管事件在中学设定，还有问题在一级预防。
While the benefits of antiplatelet therapies such as aspirin are well established in prevention of cardiovascular events in the secondary setting, there are still questions in primary prevention.
现在ACTIVEA结果加入到我们对于强效抗血小板治疗在选择性预防房颤病人卒中作用的理解中。
ACTIVE a now adds to our understanding of the role of intensive antiplatelet therapy to prevent stroke in selected patients with atrial fibrillation.
研究结果表明，抗血小板治疗未能延缓s T段抬高型心肌梗死(STEMI)后一年的冠心病(CAD)进展。
Antiplatelet therapy does not slow the progression of coronary artery disease (CAD) in the first year following ST-segment elevation myocardial infarction (STEMI), study findings indicate.
接受药物洗脱支架的患者长病变和复杂病变比接受裸金属支架的患者多，而且接受双重抗血小板治疗1年的可能性较大。
DES recipients had longer and more complex lesions than BMS recipients and also were more likely to be receiving dual antiplatelet therapy at 1 year.
目的：探讨糖尿病合并冠心病老年患者支架植入术后三联抗血小板治疗对预防支架内血栓形成和再狭窄的有效性及安全性。
Objective: To investigate the safety and efficacy of triple antiplatelet therapy in aged patients with diabetes mellitus combined with coronary heart disease after percutaneous coronary intervention.
目前，对于接受药物洗脱支架的患者，我们尝试维持双重抗血小板治疗在一年以上，因为我们非常关注晚期支架内血栓形成的可能性。
Right now, we try to keep dual anti-platelet therapy going for up to one year in patients who have a drug-eluting stent because we are very concerned about the possibility of late-stent thrombosis.
幸运的是，目前已经有一个试验正在进行，这就是DAPT研究，该研究观察了一个庞大的接受支架治疗及正在接受双重抗血小板治疗的患者群。
Fortunately, there is one ongoing right now. It is the DAPT Study, looking at a very large number of patients who have received a stent and are getting dual anti-platelet therapy.
尽管普遍认为抗凝疗法可预防静脉血栓形成，双重抗血小板疗法仍可用来治疗适应性较差的患者。
Although it is presumed that prevention of venous thrombosis is best achieved with anticoagulation, dual antiplatelet therapy can be a substitute for patients with poor compliance.
尽管普遍认为抗凝疗法可预防静脉血栓形成，双重抗血小板疗法仍可用来治疗适应性较差的患者。
Although it is presumed that prevention of venous thrombosis is best achieved with anticoagulation, dual antiplatelet therapy can be a substitute for patients with poor compliance.
应用推荐